R/E1694-data.R

In hdbayes: Bayesian Analysis of Generalized Linear Models with Historical Data

#' ECOG E1694 Trial
#'
#' A data set from the ECOG E1694 trial comparing the GM2-KLH/QS-21 (GMK) vaccine with high-dose
#' interferon alfa-2b (IFN) therapy in resected high-risk melanoma patients. The study results
#' were described in Kirkwood et al. (2001) <doi:10.1200/JCO.2001.19.9.2370>. This data set only
#' includes patients without nodal metastasis and has the same variables as the E2696 data set.
#' We can use the E2696 data as the historical data and the E1694 data as the current data.
#'
#' @name E1694
#' @docType data
#' @usage E1694
#' @keywords data
#' @format A data frame with 200 rows and 6 variables:
#' \describe{
#'   \item{failtime}{relapse-free survival (RFS) times (in months)}
#'   \item{failind}{relapse indicator, 0 = right censored, 1 = relapse}
#'   \item{treatment}{treatment indicator, 0 = GMK, 1 = IFN}
#'   \item{sex}{gender indicator, 0 = male, 1 = female}
#'   \item{age}{patient age in years}
#'   \item{perform}{ECOG performance status indicator, 0 = fully active patient, able to
#'                  carry on all pre-disease performance without restriction,
#'                  1 = restricted in physically strenuous activity, but are ambulatory
#'                  and able to carry out work of a light or sedentary nature}
#' }
#' @references
#'  Kirkwood, J. M., Ibrahim, J. G., Sosman, J. A., Sondak, V. K., Agarwala, S. S., Ernstoff, M. S., and Rao, U. (2001). High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801. Journal of Clinical Oncology, 19(9), 2370–2380.
NULL